Medpace Holdings, Inc. $MEDP Shares Purchased by LGT Fund Management Co Ltd.

LGT Fund Management Co Ltd. boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 130.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,640 shares of the company’s stock after acquiring an additional 2,060 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Medpace were worth $1,142,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group increased its position in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. increased its position in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after purchasing an additional 35 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Medpace in the 1st quarter worth $60,000. Finally, Assetmark Inc. raised its stake in shares of Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after buying an additional 43 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MEDP. Rothschild & Co Redburn downgraded Medpace from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Barclays boosted their price objective on Medpace from $300.00 to $450.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 23rd. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. TD Cowen reissued a “sell” rating and issued a $366.00 price objective (up previously from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Finally, Mizuho boosted their price objective on Medpace from $328.00 to $510.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $422.27.

Insider Activity

In other Medpace news, CEO August J. Troendle sold 36,196 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the sale, the chief executive officer owned 925,799 shares of the company’s stock, valued at $440,587,744.10. The trade was a 3.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Susan E. Burwig sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total value of $4,800,000.00. Following the sale, the vice president owned 57,500 shares of the company’s stock, valued at approximately $27,600,000. This trade represents a 14.81% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is currently owned by company insiders.

Medpace Trading Down 0.7%

MEDP opened at $532.49 on Friday. The stock has a market cap of $14.96 billion, a price-to-earnings ratio of 39.59, a PEG ratio of 3.35 and a beta of 1.40. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $547.15. The stock has a fifty day moving average price of $474.84 and a 200 day moving average price of $368.00.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to analysts’ expectations of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.